"Meno TikTok" is one of the biggest health movements online, and it's done real good — millions of women are finally talking openly about perimenopause and demanding options that were withheld for two decades. But social feeds also blur the line between well-supported hormone therapy and overhyped "custom" formulations. Here's the evidence-based version for both women and men.
Modern menopausal hormone therapy is solid within guidelines: it's the most effective treatment for hot flashes, night sweats, and genitourinary symptoms, and it protects bone. For healthy women under 60 or within 10 years of their last period, benefits generally outweigh risks.
Timing and route matter: starting near the onset of menopause has a very different risk-benefit profile than starting years later; transdermal estrogen carries less clotting risk than oral, and women with a uterus need a progestogen.
FDA-approved bioidentical hormones are legitimate; compounded "custom" BHRT is not better: a National Academies review found a lack of rigorous evidence for compounded formulations, and saliva "hormone testing" used to titrate them isn't validated.
TRT is solid for confirmed hypogonadism, not normal aging: the TRAVERSE trial found testosterone did not increase major cardiac events, but flagged higher rates of pulmonary embolism, atrial fibrillation, and kidney injury — so careful selection and monitoring still apply.
For twenty years, hormone therapy was avoided after a 2002 study (the Women's Health Initiative) reported alarming risks. The problem: that study was largely done in older women, many well past menopause, and its findings were over-generalized to everyone. A careful re-examination has substantially revised the picture.
Solid Within guidelines. The Menopause Society's current position is that menopausal hormone therapy is the most effective treatment for hot flashes, night sweats, and genitourinary symptoms, and that it also protects bone. For healthy women under 60, or within 10 years of their last period, the benefits generally outweigh the risks.
This "timing" matters: starting hormone therapy near the onset of menopause has a very different risk-benefit profile than starting it many years later. Risk is also individualized — transdermal (patch or gel) estrogen at lower doses carries less clotting risk than oral, women with a uterus need a progestogen to protect the lining, and combined therapy carries a small breast-cancer signal that rises with duration. This is a shared-decision conversation, not a one-size answer.
This is where marketing gets slippery, so the distinction is worth stating plainly.
Solid FDA-approved bioidentical hormones (e.g., estradiol, micronized progesterone). These are legitimate, well-studied, and often the preferred choice. "Bioidentical" simply means the hormone is molecularly identical to what your body makes — and many standard, FDA-approved products are exactly that.
MixedWeak Compounded "custom" bioidentical hormones (cBHT). A major National Academies review found a lack of rigorous evidence for the safety and effectiveness of compounded formulations, along with concerns about inconsistent dosing and purity, and it rejected the marketing claim that compounded equals safer or more natural. Saliva "hormone testing" used to titrate these is not validated.
The practical takeaway: you can get genuine bioidentical hormones through FDA-approved products with real evidence behind them. The "custom compounded, saliva-guided" version marketed as superior is not better — and often less proven.
Solid For confirmed hypogonadism. The Endocrine Society supports testosterone therapy for men with consistent symptoms and unequivocally low morning testosterone confirmed on repeat testing — not for normal aging or nonspecific fatigue alone. A large 2023 trial (TRAVERSE) found TRT did not increase major cardiovascular events in at-risk men, resolving a long-standing safety question.
That same trial did flag higher rates of some events — including blood clots in the lungs (pulmonary embolism), an irregular heartbeat (atrial fibrillation), and kidney injury — so TRT still calls for careful selection and monitoring. It also suppresses fertility, which matters for younger men. The "low-T" clinics that hand out testosterone based on a single borderline level and a symptom checklist are not practicing to this standard.
| Therapy | Who it's for | Our read |
|---|---|---|
| Menopausal hormone therapy (FDA-approved) | Healthy women <60 or within 10 yrs of menopause | Solid Most effective treatment for vasomotor & genitourinary symptoms; protects bone. |
| FDA-approved bioidentical hormones | Estradiol, micronized progesterone | Solid Legitimate, well-studied, often preferred. |
| Compounded "custom" BHRT (cBHT) | Saliva-guided, "custom" marketing | MixedWeak Lacks rigorous evidence; dosing/purity concerns; saliva testing unvalidated. |
| Testosterone therapy (TRT) | Confirmed hypogonadism on repeat testing | Solid Non-inferior for MACE (TRAVERSE), but higher PE/AFib/AKI; monitor closely. |
How Naya practices hormone care. We prioritize FDA-approved formulations, guideline-based eligibility and timing, and honest framing of what compounded products can and can't claim. Hormone therapy can be genuinely life-changing for the right person — and that's exactly why it deserves real diagnosis and monitoring rather than a subscription-box approach.
For the broader pattern of "custom and natural" marketing outrunning the evidence, see our functional medicine evidence guide.
For most healthy women under 60 or within 10 years of their last period, the benefits of hormone therapy generally outweigh the risks, according to the Menopause Society. Safety depends on your individual history, the type and route of hormone, and timing — which is why it's a personalized decision made with a clinician.
No. FDA-approved bioidentical hormones are well-studied and often preferred. Compounded "custom" versions lack rigorous evidence for added safety or benefit, can vary in dose and purity, and the saliva testing used to guide them isn't validated. "Natural" and "custom" don't mean better here.
Only if you have a confirmed diagnosis. Guidelines support testosterone therapy for men with consistent symptoms plus genuinely low testosterone confirmed on repeat morning testing — not for aging or nonspecific fatigue alone. It requires monitoring and can affect fertility.
Combined estrogen-progestogen therapy carries a small increase in breast-cancer risk that grows with longer duration of use, while estrogen-only therapy (for women without a uterus) has a different profile. The absolute risk for most women starting within the recommended window is low, and it's weighed against the benefits as part of an individualized discussion.
Two California locations and statewide telehealth — click a card to book, or call to schedule a consult.
21800 Devonshire St. Suite B
Chatsworth, CA 91311
601 East Arrellaga Street, Suite 101
Santa Barbara, CA 93103
Educational content, not medical advice. Speak with a qualified clinician before starting or stopping any supplement, medication, or treatment. Naya Wellness · Chatsworth & Santa Barbara, California.